Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The awards create rights to additional common shares, with vesting dependent on the recipients’ continued employment.

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) granted equity awards to nine newly hired employees on October 1, 2026, as inducements to employment.

The grants comprise options to purchase 59,250 common shares and restricted stock units, rights to receive 12,550 common shares. The options have a ten-year term and an exercise price of $18.06 per share, equal to the closing share price on the grant date. Both awards vest over four years, subject to continued employment. The Compensation Committee approved the grants under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options for 59,250 common shares at $18.06 per share create potential dilution upon exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units for 12,550 common shares create potential dilution, subject to vesting.

Key Figures

Stock options granted: 59,250 shares RSUs granted: 12,550 shares Recipients: 9 employees +4 more

Stock options granted

59,250 shares

Aggregate award to newly hired employees

RSUs granted

12,550 shares

Aggregate award to newly hired employees

Recipients

9 employees

New hires receiving inducement awards

Option exercise price

$18.06 per share

Equal to the common-stock closing price on the grant date

Option term

10 years

Stock options

Option vesting

4 years

25% after 12 months; remaining shares vest monthly over the following 36 months

RSU vesting

4 years

25% after 12 months; remaining shares vest quarterly over the following 36 months

Historical Context

1 past event · Latest: Sep 04

1 event

1. Sep 04

   Inducement grant

   24h Move

   -0.1%

   Prior awards under the same plan included options and RSUs with four-year vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"restricted stock units (“RSUs”) representing the right to receive an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 59,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,550 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

The stock options have a ten-year term, and an exercise price of $18.06 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Vor Bio grant to new employees on October 1, 2026?

Vor Bio granted nine newly hired employees options to purchase 59,250 common shares and restricted stock units representing 12,550 common shares. The options have an exercise price of $18.06 per share and a ten-year term.

How do Vor Bio’s October 1, 2026 inducement awards vest?

Both award types vest over four years, with 25% vesting after 12 months. The remaining option shares vest monthly over the following 36 months, while the remaining restricted stock units vest quarterly over the following 36 months. Vesting requires continued employment on each vesting date.